Vitestro
Vitestro is a medical robotics company pioneering autonomous blood drawing technology with its Aletta® device. This AI-driven, robotic phlebotomy solution utilizes Doppler ultrasound-guided imaging and robotic needle insertion for precise and safe blood collection. The entire process, from tourniquet application to bandaging, is automated, aiming to reduce variability, enhance reliability, and improve patient experience by minimizing anxiety and discomfort. The company collaborates with leading European hospitals and laboratories for clinical development, with over 2000 patients participating in trials and achieving milestones like CE marking for commercial use in the EU. Vitestro's mission is to address healthcare worker shortages and increasing demand for diagnostics by providing a scalable, future-proof system for blood collection.
Vitestro
Vitestro is a medical robotics company pioneering autonomous blood drawing technology with its Aletta® device. This AI-driven, robotic phlebotomy solution utilizes Doppler ultrasound-guided imaging and robotic needle insertion for precise and safe blood collection. The entire process, from tourniquet application to bandaging, is automated, aiming to reduce variability, enhance reliability, and improve patient experience by minimizing anxiety and discomfort. The company collaborates with leading European hospitals and laboratories for clinical development, with over 2000 patients participating in trials and achieving milestones like CE marking for commercial use in the EU. Vitestro's mission is to address healthcare worker shortages and increasing demand for diagnostics by providing a scalable, future-proof system for blood collection.
TL;DR
Product: Aletta® autonomous robotic phlebotomy device (ARPD) automating end-to-end blood draws
Location & founding: Founded 2017 in Utrecht, The Netherlands
Clinical progress: Completed large clinical trials (A.D.O.P.T.) with high first-stick success and patient acceptance; CE marked in 2024
Recent funding: Series A announced 2024-04-30 co-led by Sonder Capital and NYBC Ventures (~€20M / $22M)
Company Overview
Problem Domain
Diagnostic blood collection (phlebotomy) and clinical sample acquisition
Founded
2017
Industry
Medical robotics / Medtech
Funding Track Record
€20,000,000
$22M reported equivalence in some sources
€12,000,000
Earlier Series A financing announced March 21, 2023
Investor Signal
“Backers include Sonder Capital, NYBC Ventures, Invest-NL, and the European Innovation Council (EIC) Fund; Dr. Fred Moll (Sonder Capital) noted as an investor”